IDEXX LABORATORIES INC /DE Current Federal Tax Expense (Benefit)
IDEXX LABORATORIES INC /DE (IDXX) reported Current Federal Tax Expense (Benefit) of $61.68 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentFederalTaxExpenseBenefit · last filed 2026-02-20
- IDEXX LABORATORIES INC /DE current federal tax expense (benefit) for fiscal 2025 was $61.68M, a 63.30% decline from fiscal 2024.
- IDEXX LABORATORIES INC /DE current federal tax expense (benefit) for fiscal 2024 was $168.04M, a 12.15% decline from fiscal 2023.
- IDEXX LABORATORIES INC /DE current federal tax expense (benefit) for fiscal 2023 was $191.27M, a 27.43% increase from fiscal 2022.
- IDEXX LABORATORIES INC /DE current federal tax expense (benefit) for fiscal 2022 was $150.10M, a 33.05% increase from fiscal 2021.
| Period end | Current Federal Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $61.68M 10-K · filed 2026-02-20 |
| 2024-12-31 | $168.04M 10-K · filed 2026-02-20 |
| 2023-12-31 | $191.27M 10-K · filed 2026-02-20 |
| 2022-12-31 | $150.10M 10-K · filed 2025-02-21 |
| 2021-12-31 | $112.81M 10-K · filed 2024-02-22 |
| 2020-12-31 | $72.92M 10-K · filed 2023-02-16 |
| 2019-12-31 | $52.19M 10-K · filed 2022-02-16 |
| 2018-12-31 | $47.13M 10-K · filed 2021-02-12 |
| 2017-12-31 | $92.45M 10-K · filed 2020-02-14 |
| 2016-12-31 | $53.28M 10-K · filed 2019-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |